Cohesin Mutations in Core-Binding Factor Acute Myeloid Leukemia
核心结合因子急性髓系白血病的粘连蛋白突变
基本信息
- 批准号:10166800
- 负责人:
- 金额:$ 5.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AML1-ETO fusion proteinATAC-seqAcute Myelocytic LeukemiaAdult Acute Myeloblastic LeukemiaAllelesAnimal ModelApoptosisAutomobile DrivingBasic ScienceBindingBone Marrow CellsBone Marrow TransplantationCBFB geneCBFbeta-MYH11 fusion proteinCSPG6 geneCell NucleusCellsChIP-seqChildhoodChimeric ProteinsChromatinChromosomal RearrangementChromosome 16Chromosome abnormalityChromosomesClinicalComplexCore-Binding FactorDNADNA BindingDataDependenceDevelopmentDiseaseEngineeringEquipmentExhibitsFusion Oncogene ProteinsFutureGene ExpressionGene set enrichment analysisGeneticGenetic TranscriptionGenomicsGoalsHematopoiesisIn VitroKnowledgeLeadLearningMalignant NeoplasmsMentorsMolecularMusMutationMyelogenousOncogenesOncogenicOutcomePancytopeniaPathway interactionsPatientsPhenotypePhysiciansPlayPrognosisRUNX1 geneRegulationRelapseResearchResourcesRoleScientistSigns and SymptomsTestingToxic effectTrainingTransplantationUp-RegulationXCL1 genebasecellular transductionchemotherapycohesindesignexperimental studygenetic makeupgenetic signaturein vivoindividual patientleukemialeukemic transformationleukemogenesismemberpressureprognosticself-renewalt(821)(q22q22)targeted treatmenttherapeutic targettranscriptometranscriptome sequencingtreatment strategyvirtual
项目摘要
Abstract
Core-binding factor leukemia represents a subtype of AML and encompasses 30% of pediatric and 15% of adult
AMLs. The core-binding factor complex is essential in the regulation of normal hematopoiesis and is composed
of AML1 (also known as RUNX1) and CBFB. Chromosomal alterations involving the core-binding factor
complex are well-known “drivers” of leukemia development and have similar clinical and prognostic
implications. A t(8;21) leads to the fusion oncoprotein AML1-ETO and an inv(16) leads to CBFB-MYH11.
Surprisingly, these mutations alone do not induce AML in animal models, suggesting additional “hits” are
required. Mutations in one of four members of the cohesin complex (SMC1a, SMC3, RAD21, STAG1) are
commonly found in patients with AML and frequently (18-20%) co-occur with AML1-ETO, but never with
CBFB-MYH11. This suggests a selective pressure for the presence or absence of cohesin mutations depending
upon the driver oncogene. By learning more about the genetic makeup of these leukemias and how additional
mutations promote leukemogenesis, we can develop targeted therapies which will reduce both toxicity and the
relapse rate compared to existing treatments. We hypothesize that cohesin mutations synergize with
AML1-ETO during leukemic transformation, whereas cohesin mutations and CBFB-MYH11
form a synthetic lethal interaction. In Aim 1, in vivo transplant studies will be performed with AML1-
ETO;SMC3+/+ compared to AML1-ETO;SMC3+/- while CBFB-MYH11;SMC3+/+ and CBFB-MYH11; SMC3+/- will
be studied in vitro. In Aim 2, molecular studies will be performed to delve into the mechanisms driving
leukemia. ChIP-sequencing will be performed to identify changes in AML1-ETO genomic occupancy upon
introduction of cohesin haploinsufficiency. ATAC-seq and RNA-seq will be performed to identify changes in
chromatin accessibility and transcriptome of CBFB-MYH11 due to cohesin haploinsufficiency. Our preliminary
studies indicate that the loss of cohesin augments in vitro self-renewal of AML1-ETO transduced cells.
Preliminary ATAC-sequencing demonstrates that several motifs implicated in myeloid development (RUNX1,
GATA2, ERG, PU.1) are enriched in the AML1-ETO;SMC3+/- background. Further, RNA sequencing reveals
upregulation of the MYC, Rb, and E2F oncogenic gene signatures in AML1-ETO;SMC3+/- compared to SMC3+/+.
Training potential abounds for a future physician scientist within this proposal as it involves using clinical
observations to generate a hypothesis, design a research plan and develop clinical correlations based upon the
results of basic science research. Mentoring support will be easily accessible throughout this training, as will be
all necessary equipment and resources needed to complete this project.
摘要
核心结合因子白血病代表AML的一种亚型,包括30%的儿童和15%的成人
AML。核心结合因子复合物在正常造血的调节中是必不可少的,
AML 1(也称为RUNX 1)和CBFB。涉及核心结合因子的染色体改变
复合物是众所周知的白血病发展的“驱动因素”,
影响t(8;21)导致融合癌蛋白AML 1-ETO,inv(16)导致CBFB-MYH 11。
令人惊讶的是,这些突变本身不会在动物模型中诱导AML,这表明额外的“命中”是可能的。
必需的.粘着蛋白复合物的四个成员之一(SMC 1a、SMC 3、RAD 21、STAG 1)的突变是
常见于AML患者,经常(18-20%)与AML 1-ETO同时发生,但从未与
CBFB-MYH 11.这表明存在或不存在粘附素突变的选择压力取决于
在驱动癌基因上。通过更多地了解这些白血病的基因组成以及额外的
突变促进白血病发生,我们可以开发靶向治疗,这将减少毒性和
与现有治疗方法相比,复发率。我们假设,粘附素突变协同
AML 1-ETO在白血病转化过程中,而粘附素突变和CBFB-MYH 11
形成一种合成的致命的相互作用。在目标1中,将用AML 1-AML 2进行体内移植研究。
ETO; SMC 3 +/+与AML 1-ETO; SMC 3 +/-相比,而CBFB-MYH 11; SMC 3 +/+和CBFB-MYH 11; SMC 3 +/-将
在体外进行研究。在目标2中,将进行分子研究,以深入研究驱动
白血病将进行ChIP测序,以确定AML 1-ETO基因组占有率的变化,
cohesin haploinsufficiency。将进行ATAC-seq和RNA-seq,以确定
CBFB-MYH 11的染色质可及性和转录组由于粘连蛋白单倍不足。我们的初步
研究表明,粘附素的丧失增强了AML 1-ETO转导的细胞的体外自我更新。
初步的ATAC测序表明,涉及骨髓发育的几个基序(RUNX 1,
GATA 2、ERG、PU. 1)在AML 1-ETO; SMC 3 +/-背景中富集。此外,RNA测序揭示了
与SMC 3 +/+相比,AML 1-ETO; SMC 3 +/-中MYC、Rb和E2 F致癌基因特征上调。
培训潜力丰富,为未来的医生科学家在这一建议,因为它涉及使用临床
观察,以产生假设,设计研究计划,并根据观察结果开发临床相关性。
基础科学研究成果。在整个培训过程中,将很容易获得指导支持,
所有必要的设备和资源需要完成这个项目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katelyn E Heimbruch其他文献
Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis
- DOI:
10.1182/blood-2024-204339 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Nora M. Gibson;Sandra Amaral;Jesse Y Hsu;Nhat Nguyen;Meghan Haney;Katelyn E Heimbruch;Anthony Sabulski;Kimberly Ann Davidow;Katherine Lind;Samantha Scanlon;Heather Alva;L. Charles Bailey;Timothy S. Olson;Janet L. Kwiatkowski - 通讯作者:
Janet L. Kwiatkowski
Cohesin Haploinsufficiency Drives Leukemic Initiation through Fli1 Upregulation in Inv(16) AML
- DOI:
10.1182/blood-2024-200326 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Alison E Meyer;Katelyn E Heimbruch;Kirthi Pulakanti;Cary Stelloh;Josiah Murray;John A Pulikkan;Sridhar Rao - 通讯作者:
Sridhar Rao
Katelyn E Heimbruch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katelyn E Heimbruch', 18)}}的其他基金
Cohesin Mutations in Core-Binding Factor Acute Myeloid Leukemia
核心结合因子急性髓系白血病的粘连蛋白突变
- 批准号:
10430046 - 财政年份:2019
- 资助金额:
$ 5.1万 - 项目类别:
相似国自然基金
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
- 批准号:62302218
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
- 批准号:82001520
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
- 批准号:81802809
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
- 批准号:31802046
- 批准年份:2018
- 资助金额:27.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
- 批准号:31801915
- 批准年份:2018
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
- 批准号:31871331
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
相似海外基金
Project #2 Integrated single-nucleus multi-omics (ATAC-seq+RNA-seq or chromatin accessibility + RNA-seq) of human TGs
项目
- 批准号:
10806548 - 财政年份:2023
- 资助金额:
$ 5.1万 - 项目类别:
A transposase system for integrative ChIP-exo and ATAC-seq analysis at single-cell resolution
用于单细胞分辨率综合 ChIP-exo 和 ATAC-seq 分析的转座酶系统
- 批准号:
10210424 - 财政年份:2018
- 资助金额:
$ 5.1万 - 项目类别:
EAPSI: Developing Single Nucleus ATAC-seq to Map the Ageing Epigenome
EAPSI:开发单核 ATAC-seq 来绘制衰老表观基因组图谱
- 批准号:
1714070 - 财政年份:2017
- 资助金额:
$ 5.1万 - 项目类别:
Fellowship Award
A cloud-based learning module to analyze ATAC-seq and single cell ATAC-seq data
基于云的学习模块,用于分析 ATAC-seq 和单细胞 ATAC-seq 数据
- 批准号:
10558379 - 财政年份:2001
- 资助金额:
$ 5.1万 - 项目类别: